GEN Exclusives

More »

GEN Poll

More »
Dec 28, 2012

Biotech Industry Forecast

The biotech industry experienced its share of stormy weather this year, from budget cuts and the fiscal cliff to Prometheus v. Mayo and a drop in VC funds, but there were a few sunny days here and there: FDA finally issued its draft guidance on the development and approval of biosimilar drugs, and two new obesity drugs were approved by FDA, the first in more than a decade. (For more on all of the above developments, click here.) So, what does your industry forecast look like for 2013—clear sailing ahead, or should sailors take warning?

What kind of future do you predict for the biotech industry in 2013?


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »